Synovial Sarcoma
Symptoms, Doctors, Treatments, Advances & More

Synovial Sarcoma Overview

Save information for later
Sign Up

Learn About Synovial Sarcoma

What is the definition of Synovial Sarcoma?
Synovial sarcoma is a rare and aggressive soft tissue sarcoma. However, as the tumor grows larger, affected people may notice a lump or swelling. In some cases, the tumor can limit range of motion or cause numbness and/or pain if it presses on nearby nerves. Although Synovial sarcoma does not have a clearly defined cause, genetic factors are believed to influence the development of this disease. Cells in these tumors are usually characterized by the presence of a translocation involving chromosomes X and 18. This translocation is specific to Synovial sarcoma and is often used to diagnose the condition.
What are the alternative names for Synovial Sarcoma?
  • Synovial sarcoma
  • Synovial cell sarcoma
  • Synovialosarcoma
Who are the top Synovial Sarcoma Local Doctors?
Gary Schwartz
Elite in Synovial Sarcoma
Dr. Gary Schwartz
Hematology Oncology
Elite in Synovial Sarcoma
Dr. Gary Schwartz
Hematology Oncology

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
866-223-8100
Experience:
47+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gary Schwartz is a Hematologist Oncology provider in Cleveland, Ohio. Dr. Schwartz has been practicing medicine for over 47 years and is rated as an Elite provider by MediFind in the treatment of Synovial Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Fibrosarcoma, Hepato-Pancreato-Biliary Surgery, and Liver Embolization.

Melissa A. Burgess
Elite in Synovial Sarcoma
Dr. Melissa A. Burgess
Hematology Oncology
Elite in Synovial Sarcoma
Dr. Melissa A. Burgess
Hematology Oncology

UPMC Hillman Cancer Center

5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
412-623-4759
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Melissa Burgess, MD, is an assistant professor at the University of Pittsburgh School of Medicine and a medical oncologist. She specializes in the treatment of soft tissue and bone sarcomas and Merkel cell carcinoma. Dr. Burgess is rated as an Elite provider by MediFind in the treatment of Synovial Sarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Merkel Cell Carcinoma, Chondrosarcoma, and Gamma Knife Radiosurgery.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Synovial Sarcoma
Dr. Sandra D'angelo
Oncology
Elite in Synovial Sarcoma
Dr. Sandra D'angelo
Oncology

Rockefeller Outpatient Pavilion

160 E 53rd St, 
New York, NY 
646-583-3648
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sandra D'angelo is an Oncologist in New York, New York. Dr. D'angelo is rated as an Elite provider by MediFind in the treatment of Synovial Sarcoma. Her top areas of expertise are Synovial Sarcoma, Adult Soft Tissue Sarcoma, Liposarcoma, Merkel Cell Carcinoma, and Liver Embolization. Dr. D'angelo is currently accepting new patients.

View All Doctors
What are the latest Synovial Sarcoma Clinical Trials?
Phase I/Ib Study of Adoptive NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Reactive Against the NY-ESO-1-specific Cord Blood-derived NK Cells (NY-ESO-1 TCR/IL-15 NK) in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Phase I/Ib Study of Adoptive NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Reactive Against the NY-ESO-1-specific Cord Blood-derived NK Cells (NY-ESO-1 TCR/IL-15 NK) in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Enrollment Status: Recruiting
Publish Date: April 16, 2026
Intervention Type: Drug
Study Phase: Phase 1

Summary: The goal of this clinical research study is to find a recommended dose of donated NK cells that can be given along with chemotherapy to patients with advanced cancers. The safety and effects of this therapy will also be studied.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Single-arm Open-label Phase I/II Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Single-arm Open-label Phase I/II Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Enrollment Status: Recruiting
Publish Date: April 14, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center